Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

NCT03728972 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

19

Enrollment

OTHER

Sponsor class

Conditions

NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis)
NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)

Interventions

DRUG: Pembrolizumab

Sponsor

Memorial Sloan Kettering Cancer Center